Berlin-based biotechnology firm Tacalyx has successfully secured €11 million in a seed extension financing round to advance its pioneering cancer therapies. This funding coincides with the selection of its first clinical candidate, TCX-201, an antibody-drug conjugate aimed at treating solid tumours. The company is now focused on moving this lead program through preclinical development with the goal of reaching clinical trials by 2027.
Strategic Funding to Propel Clinical Development
The €11 million investment represents the first closing of the seed extension round and was provided by Tacalyx's existing international investor syndicate. Key backers include Boehringer Ingelheim Venture Fund, Kurma Partners, High-Tech Gründerfonds, Eurazeo, Creathor Ventures, and Thuja Capital. The company has indicated its intention to expand the round with additional investors in a subsequent closing to further bolster its financial position.
Proceeds from the financing are earmarked to guide the lead candidate, TCX-201, through essential preclinical studies required for a clinical trial application. This capital infusion will also enable Tacalyx to continue advancing and expanding its broader pipeline of innovative cancer treatments. The company's strategy involves leveraging its platform to develop multiple first-in-class programs targeting various solid tumour indications with high unmet medical needs.
Pioneering a New Class of Cancer Targets
TCX-201 is an antibody-drug conjugate (ADC) developed against an undisclosed Tumour Associated Carbohydrate Antigen (TACA). This candidate was designed using the company’s proprietary platform for the treatment of gastrointestinal malignancies and other solid tumours. TACAs represent a promising, yet largely untapped, class of targets found on the surface of tumour cells, offering a path to highly selective therapies.
These unique glycan structures are overexpressed on cancer cells and play a critical role in tumour progression, including immune evasion and metastasis. Because TACAs are present across a wide range of cancer types, they are attractive targets for developing pan-cancer therapeutics. Their consistent expression, even in tumours resistant to standard treatments, makes them a differentiated and valuable focus for new drug development.
Historically, TACAs have been considered difficult to address with conventional antibody approaches, leaving their therapeutic potential largely unexplored. Tacalyx has developed a proprietary discovery platform capable of generating high-affinity antibodies against these complex targets. This breakthrough technology effectively makes previously undruggable targets accessible, paving the way for novel antibody-based treatments like ADCs and multi-specifics.
Leadership and Vision for Future Growth
Jean Engela, CEO of Tacalyx, expressed gratitude for the investors' commitment and highlighted the company's transition toward clinical development. He affirmed the team's focus on translating its cutting-edge science into transformative therapies for cancer patients. The selection of TCX-201 marks a new stage for the company as it progresses its lead program toward the clinic.
Klaus Schollmeier, Chairman of the Board, commented on the company's success in unlocking the therapeutic potential of TACAs. He noted that Tacalyx is rapidly evolving from a discovery research organization into a clinical-stage biotech company. Schollmeier praised the team for its significant achievements in advancing both its lead candidate and its earlier-stage pipeline.
With a clear development path for TCX-201, Tacalyx is also looking toward its next milestones to build a robust portfolio. The company plans to select its next clinical candidate by the end of 2026. This demonstrates a sustained effort to build a deep pipeline of therapies designed to address solid tumours with significant unmet needs.
The recent funding and selection of a lead clinical candidate represent a pivotal moment for Tacalyx, validating its innovative approach to oncology. By targeting the challenging class of TACAs, the company is positioned to make a significant impact on the treatment landscape for solid tumours. This progress brings new hope for developing more effective and highly selective therapies for patients with hard-to-treat cancers.